GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stevanato Group SPA (NYSE:STVN) » Definitions » EV-to-EBITDA
中文

Stevanato Group SPA (Stevanato Group SPA) EV-to-EBITDA : 26.46 (As of Apr. 25, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Stevanato Group SPA EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Stevanato Group SPA's enterprise value is $7,772 Mil. Stevanato Group SPA's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $294 Mil. Therefore, Stevanato Group SPA's EV-to-EBITDA for today is 26.46.

The historical rank and industry rank for Stevanato Group SPA's EV-to-EBITDA or its related term are showing as below:

STVN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 14.16   Med: 24.99   Max: 36.41
Current: 26.46

During the past 6 years, the highest EV-to-EBITDA of Stevanato Group SPA was 36.41. The lowest was 14.16. And the median was 24.99.

STVN's EV-to-EBITDA is ranked worse than
75.05% of 489 companies
in the Medical Devices & Instruments industry
Industry Median: 15.23 vs STVN: 26.46

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-25), Stevanato Group SPA's stock price is $27.31. Stevanato Group SPA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.593. Therefore, Stevanato Group SPA's PE Ratio for today is 46.05.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Stevanato Group SPA EV-to-EBITDA Historical Data

The historical data trend for Stevanato Group SPA's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stevanato Group SPA EV-to-EBITDA Chart

Stevanato Group SPA Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial - - 22.32 17.36 25.59

Stevanato Group SPA Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.36 29.10 33.17 27.77 25.59

Competitive Comparison of Stevanato Group SPA's EV-to-EBITDA

For the Medical Instruments & Supplies subindustry, Stevanato Group SPA's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stevanato Group SPA's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Stevanato Group SPA's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Stevanato Group SPA's EV-to-EBITDA falls into.



Stevanato Group SPA EV-to-EBITDA Calculation

Stevanato Group SPA's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=7772.345/293.781
=26.46

Stevanato Group SPA's current Enterprise Value is $7,772 Mil.
Stevanato Group SPA's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $294 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Stevanato Group SPA  (NYSE:STVN) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Stevanato Group SPA's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=27.31/0.593
=46.05

Stevanato Group SPA's share price for today is $27.31.
Stevanato Group SPA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.593.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Stevanato Group SPA EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Stevanato Group SPA's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Stevanato Group SPA (Stevanato Group SPA) Business Description

Traded in Other Exchanges
Address
Via Molinella 17, Piombino Dese, Padua, ITA, 35017
Stevanato Group SPA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. Stevanato's revenue is geographically diversified, with 60% of sales from Europe, the Middle East and Africa (EMEA), 27% in North America, 10% in Asia-Pacific (APAC), and 3% from South America. It has two segments Biopharmaceutical and Diagnostic Solutions and Engineering.